<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article xml:lang="EN" article-type="research-article">

<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id>
<journal-id journal-id-type="publisher-id">YMJ</journal-id>
<journal-title-group>
<journal-title>Yonsei Medical Journal</journal-title>
</journal-title-group>
<issn pub-type="ppub">0513-5796</issn>
<publisher>
<publisher-name>Yonsei University College of Medicine</publisher-name>
</publisher>
</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.3349/ymj.1990.31.4.347</article-id>
			<article-categories>
				<subj-group>
					<subject>Original Article</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Circulating immune complexes and cell-mediated immunity in patients with hepatitis B virus associated liver diseases</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<name>
						<surname>Kim</surname>
						<given-names>Sang Ae</given-names>
					</name>
					<xref ref-type="aff" rid="A1"></xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Lee</surname>
						<given-names>Sang In</given-names>
					</name>
					<xref ref-type="aff" rid="A1"></xref>
				</contrib>
				<contrib contrib-type="author">
				<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9851-0137</contrib-id>
					<name>
						<surname>Choi</surname>
						<given-names>In Hong</given-names>
					</name>
					<xref ref-type="aff" rid="A1"></xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Shin</surname>
						<given-names>Jeon Soo</given-names>
					</name>
					<xref ref-type="aff" rid="A1"></xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Uhm</surname>
						<given-names>Jeong Ran</given-names>
					</name>
					<xref ref-type="aff" rid="A1"></xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Kim</surname>
						<given-names>Se Jong</given-names>
					</name>
					<xref ref-type="aff" rid="A1"></xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Choi</surname>
						<given-names>Heung Jai</given-names>
					</name>
					<xref ref-type="aff" rid="A1"></xref>
				</contrib>
			</contrib-group>
				<aff id="A1">Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.</aff>
				<aff id="A2">Department of Microbiology, Yonsei University College of Medicine, Seoul, Korea.</aff>
			<pub-date pub-type="ppub">
				<month>12</month>
				<year>1990</year>
			</pub-date>
			<pub-date pub-type="epub">
				<day>20</day>
				<month>02</month>
				<year>2002</year>
			</pub-date>
			<volume>31</volume>
			<issue>4</issue>
			<fpage>347</fpage>
			<lpage>358</lpage>
			<permissions>
				<copyright-statement>Copyright &#x00A9; 1990 The Yonsei University College of Medicine</copyright-statement>
				<copyright-year>1990</copyright-year>
			</permissions>
			<abstract>
				<p>The prevalence of circulating immune complexes (CIC), their role and their relationship to cell-mediated immunity in patients with hepatitis B virus associated liver disease are still controversial. This study was designed to investigate the prevalence of CIC and their relationship to viral markers, to subsets of peripheral blood T lymphocytes and to suppressor cell activity in patients with hepatitis B virus associated liver diseases. CIC were positive in 29.3&#x0025; of 41 healthy HBsAg carriers, 37.8&#x0025; of 88 patients with hepatitis B virus associated liver diseases, and 15&#x0025; of 41 healthy subjects by the platelet aggregation test (PAT). The prevalence of CIC in patients with acute hepatitis (40.0&#x0025;) and in those with cirrhosis (61.5&#x0025;) was significantly higher than in normal controls (p &#x003C; 0.05, p &#x003C; 0.005 respectively). There was no correlation between the titer of CIC and serum HBsAg titer or the status of HBeAg, and no significant decrease in the peripheral blood lymphocyte CD4/CD8 ratio in healthy HBsAg carriers (1.39 &#x00B1; 0.31) and in patients with liver diseases (1.40 &#x00B1; 0.54) compared to the normal controls (1.48 &#x00B1; 0.31). Concanavalin A induced suppressor cell activity on IgG producing cells was impaired in healthy HBsAg carriers (34.9&#x0025;) (p &#x003C; 0.005) and in patients with liver diseases (25.3&#x0025;) (p &#x003C; 0.0001), and this change was prominent in patients with chronic active hepatitis and cirrhosis (p &#x003C; 0.0001). And there was a significant reverse correlation between concanavalin A induced suppressor cell activity on IgG-producing cells and the titer of CIC in PAT positive patients with hepatitis B virus associated liver diseases. In conclusion, it was suggested that defective suppressor cell function may lead to an increased B cell activation and such activity may account for the presence of CIC.</p>
				</abstract>
				<kwd-group>
					<kwd>Circulating immune complexes</kwd>
					<kwd>cell-mediated immunity</kwd>
					<kwd>hepatitis B virus associated liver diseases</kwd>
				</kwd-group>
			</article-meta>
		</front>
	</article>
	
